NVP-BEP800

Confirm delete?

NVP-BEP800

Zoom

Cat No: 18383

Biochemicals - Small Molecule Inhibitors

NVP-BEP800 is an inhibitor of heat shock protein 90 (Hsp90; IC50 = 58 nM for recombinant human Hsp90β).{29919} It is selective for Hsp90 over the chaperones GRP94 and TRAP1 (IC50s = 4.1 and 5.5 µM, respectively). NVP-BEP800 inhibits the growth of BT47...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

2-amino-4-[2,4-dichloro-5-[2-(1-pyrrolidinyl)ethoxy]phenyl]-N-ethyl-thieno[2,3-d]pyrimidine-6-carboxamide

Correlated keywords:

NVPBEP800 NVPBEP 800 BEP 800 Hsp-90 90? 70 GRP 94 TRAP 1 BT 474 SKBR3 SKBR 3 BR3 MCF7 MDAMB157 MDAMB 157 MDAMB231 231 MDAMB468 468 BT20 HERr 2 A 375 L1 T2

Product Overview:
NVP-BEP800 is an inhibitor of heat shock protein 90 (Hsp90; IC50 = 58 nM for recombinant human Hsp90β).{29919} It is selective for Hsp90 over the chaperones GRP94 and TRAP1 (IC50s = 4.1 and 5.5 µM, respectively). NVP-BEP800 inhibits the growth of BT474, SK-BR-3, MCF-7, MDA-MB-157, MDA-MB-231, MDA-MB-468, and BT-20 breast cancer cells (GI50s = 53, 56, 118, 89, 190, 173, and 162 nM, respectively). It reduces levels of the Hsp90 target proteins HER2 and Raf-1 in MCF-7 cells. NVP-BEP800 induces apoptosis and attenuates X-ray-induced increases in Hsp70 levels in T98G glioblastoma cells.{29922} NVP-BEP800 (15-50 mg/kg) reduces tumor volume in A375 melanoma and BT474 breast cancer mouse xenograft models.{29919} It also reduces tumor volume in an L1T2 Kaposi sarcoma mouse xenograft model.{29918}

Size	500 µg
Shipping	dry ice
CAS Number	847559-80-2
Molecular Formula	C₂₁H₂₃Cl₂N₅O₂S
SMILES	ClC1=CC(Cl)=C(OCCN2CCCC2)C=C1C3=C4C(SC(C(NCC)=O)=C4)=NC(N)=N3
Molecular Weight	480,4
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2903.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.